Third Circuit Could See Rise In Pay-for-Delay Litigation

, The Legal Intelligencer


The ultimate winner in the U.S. Supreme Court's decision that pharmaceutical pay-for-delay settlements are subject to antitrust review might not be the Federal Trade Commission or drug manufacturers, but the attorneys who represent them.

This premium content is reserved for New Jersey Law Journal subscribers.

Continue reading by getting started with a subscription.

Already a subscriber? Log in now

What's being said

Comments are not moderated. To report offensive comments, click here.

Preparing comment abuse report for Article #1202607994696

Thank you!

This article's comments will be reviewed.